U.S. markets closed

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
40.68-0.05 (-0.12%)
Al cierre: 04:00PM EDT
40.86 +0.18 (+0.44%)
Fuera de horario: 07:15PM EDT

Halozyme Therapeutics, Inc.

12390 El Camino Real
San Diego, CA 92130
United States
858 794 8889
https://halozyme.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo373

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.President, CEO & Director1.82M5.69M1963
Ms. Nicole LaBrosseSenior VP & CFO849.36kN/D1983
Dr. Michael J. LaBarre Ph.D.Senior VP & Chief Technical Officer843.89k2.6M1964
Mr. Mark Snyder Esq.Senior VP & Chief Legal Officer912.87kN/DN/D
Ms. Cortney Caudill M.B.A.Chief Operations OfficerN/DN/DN/D
Ms. Tram BuiHead of Investor Relations & Corporate CommunicationsN/DN/DN/D
Ms. Amy Marinne FoxChief Human Resources OfficerN/DN/DN/D
Dr. Steve Knowles MBBSChief Medical OfficerN/DN/DN/D
Dr. Christopher Bryant Ph.D.Chief Manufacturing Officer & Head of Technical OperationsN/DN/D1961
Ms. Kristin SchwartzbauerHead of QualityN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Halozyme Therapeutics, Inc. a partir del 1 de marzo de 2024 es 2. Las puntuaciones principales son Auditoría: 4; Junta: 1; Derechos del accionista: 3; Compensación: 2.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.